Prelude Therapeutics (PRLD) executive Huang acquired 9,375 shares
Insider transactions reported
Jane Huang (President, CMO at Prelude Therapeutics Incorporated, PRLD) reported that they acquired 9,375 shares, and gave up 3,844 shares at $3.77 to cover taxes or an exercise price on Jan 4, 2024. After these transactions the filing shows 45,259 shares held directly.
- Reporting person
- Huang Jane
- Role
- President, CMO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 4, 2024 | Exercise or conversion of a derivative (M) | Common Stock1 | +9,375 | - | - | 49,103 direct |
| Jan 4, 2024 | Shares withheld for taxes or exercise price (F) | Common Stock2 | -3,844 | $3.77 | $14.5K | 45,259 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 4, 2024 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 9,375 Common Stock1, 3 | -9,375 | - | - | 84,375 direct |
Holdings before and after
- Common Stock: 39,728 to 45,259 direct
- Restricted Stock Unit: 93,750 to 84,375 direct
Footnotes from the filing
- 1. Each Restricted Stock Unit ( RSU ) represents a contingent right to receive one share of Issuer's Common Stock.
- 2. Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
- 3. The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Huang report in this PRLD Form 4?
Jane Huang (President, CMO at Prelude Therapeutics Incorporated, PRLD) reported that they acquired 9,375 shares, and gave up 3,844 shares at $3.77 to cover taxes or an exercise price on Jan 4, 2024. After these transactions the filing shows 45,259 shares held directly.
How many PRLD shares does Huang hold after this filing?
The filing shows 45,259 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for PRLD
Earlier insider filings at PRLD
- Dec 13, 2023SEC Form 4 filed by Baker Bros. Advisors Lp
- Oct 6, 2023Huang Jane converted options into 9,375 shares, increasing direct ownership by 31% to 39,728 units (SEC Form 4)
- Jul 6, 2023SEC Form 4 filed by Huang Jane
- Jun 21, 2023SEC Form 4 filed by Baker Bros. Advisors Lp
- Jun 21, 2023SEC Form 4 filed by Sandor Victor
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Follow PRLD and get a push notification the moment its next story breaks.